STOCK TITAN

Sonoma Pharmaceu Stock Price, News & Analysis

SNOA Nasdaq

Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.

Sonoma Pharmaceuticals, Inc. (SNOA) delivers innovative healthcare solutions through its patented Microcyn® technology, specializing in stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and animal health. This page provides a centralized resource for tracking the company’s latest developments, regulatory milestones, and strategic initiatives.

Access timely updates on FDA clearances, clinical study results, and product launches that demonstrate SNOA’s commitment to non-toxic, evidence-based therapies. Investors and healthcare professionals will find verified information about:

• New product approvals across global markets
• Partnership announcements with medical distributors
• Financial performance and growth strategies
• Research breakthroughs in HOCl applications

All content is curated to meet strict accuracy standards, with direct links to official press releases and validated third-party analyses. Bookmark this page for efficient monitoring of SNOA’s progress in advancing biocompatible wound care and antimicrobial solutions.

Rhea-AI Summary

Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 14% increase in Q4 2024 revenues to $3.4 million, driven by rising product sales across all territories except 'Rest of the World'. Gross profit margin improved by 3% year-over-year to 32%. Despite a 24% rise in operating expenses due to increased R&D, net loss decreased by 18% to $1.1 million. For FY 2024, revenues dropped 4.5% to $12.7 million due to lower service revenue but gross profit margin increased to 37%. Net loss for the year improved by 6% to $4.8 million. CEO Amy Trombly highlighted product innovation and market expansion as key growth drivers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
-
Rhea-AI Summary

Sonoma Pharmaceuticals, Inc. announced the availability of its MicrocynAH animal health care products in Menards home improvement stores. The products include a range of items for wound care, eye and ear care, and itch relief for various animals. The expansion aims to provide pet owners with safe and effective solutions for their pets' health needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
-

FAQ

What is the current stock price of Sonoma Pharmaceu (SNOA)?

The current stock price of Sonoma Pharmaceu (SNOA) is $3.61 as of July 11, 2025.

What is the market cap of Sonoma Pharmaceu (SNOA)?

The market cap of Sonoma Pharmaceu (SNOA) is approximately 4.9M.
Sonoma Pharmaceu

Nasdaq:SNOA

SNOA Rankings

SNOA Stock Data

4.88M
1.62M
1.25%
1.26%
0.6%
Drug Manufacturers - Specialty & Generic
Surgical & Medical Instruments & Apparatus
Link
United States
BOULDER